BioSpace News Archive

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of MCLA-145, the Company’s clinical stage Biclonics® T-cell agonist.

ViaCyte, Inc., an innovator in cellular therapy and regenerative medicine, announced that it has appointed Jon Wilensky, MD, MBA, FACS, as Head of Surgery.

Viracta Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Viracta’s Investigational New Drug (IND) application to proceed into a Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors.

Axon Therapies today announced the appointment of seasoned medical device executive Chad Hoskins as Chief Executive Officer (CEO).

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2021 financial results on Wednesday, August 4, 2021, before the open of the US financial markets.

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.

Surface Ophthalmics, Inc. today announced it has secured gross proceeds of approximately $25 million in a private placement of preferred stock, at a purchase price of $4.50 per share.

Amfora, Inc., a biotechnology company that is using gene editing to increase the protein density of soybean and other crops to fuel the plant-based protein revolution, announced an expansion to its Series B round to a total of $7 million with new investment from the global player and stock listed company BayWa AG.

Omniscient Neurotechnology today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Quicktome™, a digital brain mapping platform that allows neurosurgeons to visualize and understand a patient’s brain networks prior to performing life-changing brain surgery.

Vericel Corporation today announced the following webcast and conference call to discuss its second-quarter 2021 financial results and business highlights.